Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

NCT04065555 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: TAK-981
BIOLOGICAL: Cetuximab
BIOLOGICAL: Avelumab
COMBINATION_PRODUCT: TAK-981 + Cetuximab
COMBINATION_PRODUCT: TAK-981 + Avelumab

Sponsor

Presage Biosciences

Collaborators

[object Object]